4 Best Biotech Stocks According to POWR Ratings

[Investing Insights Daily]( May 23rd, 2023 SPONSORED AD [He's got a higher win rate than Buffett, Icahn, and Cuban...]( For nearly a decade now, he's been helping investors navigate any curveball the market decides to throw at us... In fact, with his simple system... he's not just surviving this market... he's thriving in it. In fact, he hasn't closed out a single losing trade all year! [Want the full story? Click here]( [4 Best Biotech Stocks According to POWR Ratings]( The biotech industry has diversified and thrived, especially during the pandemic, owing to the advanced innovations and incessant efforts to curb the deadly virus. Moreover, the inelastic demand enjoyed by the industry makes it well-grounded to maintain its buoyancy in the upcoming times. Against this backdrop, let us explore some biotech stocks Amgen Inc. ([AMGN]( – [Get Rating]( Regeneron Pharmaceuticals, Inc. ([REGN]( – [Get Rating]( United Therapeutics Corporation ([UTHR]( – [Get Rating]( and Vanda Pharmaceuticals Inc. ([VNDA]( – [Get Rating]( with overall A (Strong Buy) ratings in our proprietary [POWR Ratings]( system. The biotech industry has immense potential to generate tremendous [opportunities for society]( such as improving healthcare quality, increasing agricultural production, and producing a cleaner environment. The industry provided 2.1 million jobs and had a [$2.9 trillion]( impact on the U.S. economy in 2021. Even though [macroeconomic challenges]( prevail, incredible scientific, medical, and technological breakthroughs are poised to keep the biotech industry on an upward trajectory, especially since biotechnology has [numerous applications](. Also, on the backs of [strong government initiatives]( aimed at the modernization of regulatory framework, bolstering of supply chains, and supporting the innovation ecosystem, the global biotechnology market size is poised to grow at a [CAGR of 14%]( from 2023 to 2030. Furthermore, over the past six months, the SPDR S&P Biotech ETF ([XBI]( has gained 8%, outpacing the S&P 500’s gains of 4.7%, substantiating investors’ interest in biotech stocks. Hence, investors could capitalize on… Continue reading at [STOCKNEWS.com]( Copyright © 2023 StockNews.com | All Rights Reserved [Unsubscribe]( Magnifi Communities, 1 Penn Plaza, Suite 3910, New York, NY 10019